Vistagen reports preliminary open-label data from PALISADE-4 extension for fasedienolSep 22Clinical readoutVistaGen Therapeutics, Inc.
Vistagen plans FDA meeting on fasedienol path after mixed PALISADE-4 dataAug 14Quarterly updateVistaGen Therapeutics, Inc.
Vistagen reports Phase 2 repeat dose results for fasedienol in social anxiety disorderAug 6Clinical readoutVistaGen Therapeutics, Inc.
Vistagen's fasedienol misses primary endpoint in PALISADE-4 trialJun 30Clinical readoutVistaGen Therapeutics, Inc.
